These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19739356)

  • 1. The timing of adoption of positron emission tomography: a real options approach.
    Pertile P; Torri E; Flor L; Tardivo S
    Health Care Manag Sci; 2009 Sep; 12(3):217-27. PubMed ID: 19739356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography.
    Pertile P
    Int J Health Care Finance Econ; 2009 Sep; 9(3):317-32. PubMed ID: 19152067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal timing of multiple investment decisions in a wood value chain: A real options approach.
    Tschulkow M; Compernolle T; Van Passel S
    J Environ Manage; 2021 Jul; 290():112590. PubMed ID: 33910072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delaying investments in sensor technology: The rationality of dairy farmers' investment decisions illustrated within the framework of real options theory.
    Rutten CJ; Steeneveld W; Oude Lansink AGJM; Hogeveen H
    J Dairy Sci; 2018 Aug; 101(8):7650-7660. PubMed ID: 29729913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the capital efficiency of healthcare information technologies investments: an econometric perspective.
    Meyer R; Degoulet P
    Yearb Med Inform; 2008; ():114-27. PubMed ID: 18660886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
    Mansueto M; Grimaldi A; Mangili G; Picchio M; Giovacchini G; Viganò R; Messa C; Fazio F
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):612-9. PubMed ID: 19549284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
    Nguyen VH; Peloquin S; Lacasse Y
    Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making real options really work.
    van Putten AB; MacMillan IC
    Harv Bus Rev; 2004 Dec; 82(12):134-41, 150. PubMed ID: 15605572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity-based costing evaluation of a [(18)F]-fludeoxyglucose positron emission tomography study.
    Krug B; Van Zanten A; Pirson AS; Crott R; Borght TV
    Health Policy; 2009 Oct; 92(2-3):234-43. PubMed ID: 19446356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A managerial approach to costing fixed assets in health care organizations: the role of depreciation and interest.
    Goldschmidt Y; Gafni A
    Health Care Manage Rev; 1991; 16(4):55-65. PubMed ID: 1743964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of real options on willingness to pay for mortality risk reductions.
    Krüger NA; Svensson M
    J Health Econ; 2009 May; 28(3):563-9. PubMed ID: 19261344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.
    Cao JQ; Rodrigues GB; Louie AV; Zaric GS
    Clin Lung Cancer; 2012 May; 13(3):161-70. PubMed ID: 22133290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investment appraisal approach to clinical trial design.
    Backhouse ME
    Health Econ; 1998 Nov; 7(7):605-19. PubMed ID: 9845254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost characteristics of hospitals.
    Smet M
    Soc Sci Med; 2002 Sep; 55(6):895-906. PubMed ID: 12220092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of positron emission tomography in breast cancer.
    Sloka JS; Hollett PD; Mathews M
    Mol Imaging Biol; 2005; 7(5):351-60. PubMed ID: 16086227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real options reasoning in healthcare: an integrative approach and synopsis.
    Williams DR; Hammes PH
    J Healthc Manag; 2007; 52(3):170-86; discussion 187. PubMed ID: 17552354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifetime earnings patterns, the distribution of future Social Security benefits, and the impact of pension reform.
    Bosworth B; Burtless G; Steuerle E
    Soc Secur Bull; 2000; 63(4):74-98. PubMed ID: 11641991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.